CA
NZ
UK
AU
IND
US
Silexion Therapeutics has appointed Avner Lushi to its audit committee, effectively filling the vacancy left by Professor Peled's resignation, which took effect on August 1, 2026. Professor Peled stepped down for personal reasons, clarifying that the decision was not due to any disagreements over …
Stoke Therapeutics posted Q2 earnings per share of $‑0.79, topping the $‑0.84 consensus, while its stock slipped 1.2% to $29.21. The beat narrows valuation concerns, but the modest price decline reflects lingering skepticism over upcoming Phase 3 data and timing of the FDA meeting.Key …
The recent accident involving a teenager crashing into another driver underscores critical questions around Medicare’s liability for covering hospital bills. The injured party reported that their car was nearly 20 years old and only had liability and uninsured motorist insurance, excluding collision coverage. This …
Teladoc Health (NYSE: TDOC) announced a board expansion that lifts its director count to ten, appointing veteran executive Mark V. Anquillare as a new member. Anquillare will join both the audit and compensation committees, positioning the company for stronger oversight.
Teleflex Inc (NYSE: TFX) has successfully divested its Original Equipment Manufacturing (OEM) business for $1.5 billion, a strategic decision expected to enhance the company's financial flexibility and shareholder returns. The transaction positions Teleflex to prioritize its core operations while utilizing approximately $1.25 billion of …
Mixed earnings reports from major biotech companies have resulted in diverging outcomes for investors. Increased operating expenses were the heart of the issue, leading analysts to express surprise at the scale of the miss. On the other hand, Twist Bioscience also faced challenges, generating …
UFP Technologies Inc's net income rose 21.4% to $20.9 million in Q2, driven by 15.1% sales growth, which may support the stock's 19.8% year-to-date gain.Key HighlightsTop five customers grew 14.7%MedTech business grew 19.7%Operating income grew 15.5% to $28.1 millionThe company's strong execution and growth …
Vertex Pharmaceuticals (NASDAQ: VRTX) lifted its full‑year 2026 revenue outlook to a $13.1‑$13.2 billion range, a 1 % increase from the previous $12.95‑$13.1 billion corridor.
Viemed Healthcare's revenue increased 23.9% to $78.1 million, driven by growth in ventilator and PAP therapy patients, and the company raised its full-year guidance. This increase in revenue is significant for investors as it demonstrates the company's ability to expand its patient base and …
Stoke Therapeutics (NASDAQ: STOK) posted a cash balance of $420.0 million, up from $354.3 million, after securing $65.7 million in an at‑the‑market sale. The infusion of liquidity pushes the company's runway out to early 2028, ensuring it can sustain the costly development and potential …
Please wait processing your request...